Enovis Corporation (ENOV) Stock Competitors & Peer Comparison
See (ENOV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ENOV | $23.96 | +1.18% | 1.4B | -1.20 | -$19.89 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $91.25 | +0.83% | 158.9B | 25.70 | $3.55 | +2.67% |
| ISRG | $426.61 | +1.91% | 151.1B | 51.71 | $8.25 | N/A |
| SYK | $314.01 | +4.14% | 120.4B | 36.31 | $8.65 | +1.09% |
| MDT | $81.98 | +1.60% | 105.2B | 21.98 | $3.73 | +3.46% |
| BSX | $48.96 | +0.53% | 72.7B | 20.47 | $2.39 | N/A |
| BRKRP | $425.35 | +1.40% | 64.6B | N/A | N/A | +0.35% |
| EW | $87.54 | +1.97% | 50.4B | 47.31 | $1.85 | N/A |
| DXCM | $78.19 | +2.05% | 30.2B | 33.56 | $2.33 | N/A |
Stock Comparison
ENOV vs BSX-PA Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ENOV is priced at $23.96, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ENOV's ROE is -0.60%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check BSX-PA's competition here
ENOV vs ABT Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ABT has a market cap of 158.9B. Regarding current trading prices, ENOV is priced at $23.96, while ABT trades at $91.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ABT's P/E ratio is 25.70. In terms of profitability, ENOV's ROE is -0.60%, compared to ABT's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ABT's competition here
ENOV vs ISRG Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ISRG has a market cap of 151.1B. Regarding current trading prices, ENOV is priced at $23.96, while ISRG trades at $426.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ISRG's P/E ratio is 51.71. In terms of profitability, ENOV's ROE is -0.60%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, ENOV is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ISRG's competition here
ENOV vs SYK Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, SYK has a market cap of 120.4B. Regarding current trading prices, ENOV is priced at $23.96, while SYK trades at $314.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas SYK's P/E ratio is 36.31. In terms of profitability, ENOV's ROE is -0.60%, compared to SYK's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SYK's competition here
ENOV vs MDT Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, MDT has a market cap of 105.2B. Regarding current trading prices, ENOV is priced at $23.96, while MDT trades at $81.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas MDT's P/E ratio is 21.98. In terms of profitability, ENOV's ROE is -0.60%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check MDT's competition here
ENOV vs BSX Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, BSX has a market cap of 72.7B. Regarding current trading prices, ENOV is priced at $23.96, while BSX trades at $48.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas BSX's P/E ratio is 20.47. In terms of profitability, ENOV's ROE is -0.60%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check BSX's competition here
ENOV vs BRKRP Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, BRKRP has a market cap of 64.6B. Regarding current trading prices, ENOV is priced at $23.96, while BRKRP trades at $425.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas BRKRP's P/E ratio is N/A. In terms of profitability, ENOV's ROE is -0.60%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, ENOV is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check BRKRP's competition here
ENOV vs EW Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, EW has a market cap of 50.4B. Regarding current trading prices, ENOV is priced at $23.96, while EW trades at $87.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas EW's P/E ratio is 47.31. In terms of profitability, ENOV's ROE is -0.60%, compared to EW's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check EW's competition here
ENOV vs DXCM Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, DXCM has a market cap of 30.2B. Regarding current trading prices, ENOV is priced at $23.96, while DXCM trades at $78.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas DXCM's P/E ratio is 33.56. In terms of profitability, ENOV's ROE is -0.60%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, ENOV is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check DXCM's competition here
ENOV vs RMD Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, RMD has a market cap of 28.6B. Regarding current trading prices, ENOV is priced at $23.96, while RMD trades at $196.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas RMD's P/E ratio is 19.00. In terms of profitability, ENOV's ROE is -0.60%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ENOV is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check RMD's competition here
ENOV vs PHG Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, PHG has a market cap of 25.7B. Regarding current trading prices, ENOV is priced at $23.96, while PHG trades at $26.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas PHG's P/E ratio is 22.84. In terms of profitability, ENOV's ROE is -0.60%, compared to PHG's ROE of +0.09%. Regarding short-term risk, ENOV is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check PHG's competition here
ENOV vs STE Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, STE has a market cap of 20.8B. Regarding current trading prices, ENOV is priced at $23.96, while STE trades at $212.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas STE's P/E ratio is 26.88. In terms of profitability, ENOV's ROE is -0.60%, compared to STE's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check STE's competition here
ENOV vs ZBH Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ZBH has a market cap of 17.3B. Regarding current trading prices, ENOV is priced at $23.96, while ZBH trades at $89.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ZBH's P/E ratio is 23.22. In terms of profitability, ENOV's ROE is -0.60%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ENOV is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ZBH's competition here
ENOV vs ABMD Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ENOV is priced at $23.96, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ENOV's ROE is -0.60%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ABMD's competition here
ENOV vs SNN Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, SNN has a market cap of 13.3B. Regarding current trading prices, ENOV is priced at $23.96, while SNN trades at $31.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas SNN's P/E ratio is 21.91. In terms of profitability, ENOV's ROE is -0.60%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SNN's competition here
ENOV vs ALGN Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ALGN has a market cap of 12.8B. Regarding current trading prices, ENOV is priced at $23.96, while ALGN trades at $178.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ALGN's P/E ratio is 29.93. In terms of profitability, ENOV's ROE is -0.60%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ALGN's competition here
ENOV vs PEN Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, ENOV is priced at $23.96, while PEN trades at $321.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas PEN's P/E ratio is 74.16. In terms of profitability, ENOV's ROE is -0.60%, compared to PEN's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check PEN's competition here
ENOV vs SWAV Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ENOV is priced at $23.96, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ENOV's ROE is -0.60%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ENOV is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SWAV's competition here
ENOV vs GMED Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, GMED has a market cap of 11.1B. Regarding current trading prices, ENOV is priced at $23.96, while GMED trades at $82.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas GMED's P/E ratio is 19.29. In terms of profitability, ENOV's ROE is -0.60%, compared to GMED's ROE of +0.13%. Regarding short-term risk, ENOV is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check GMED's competition here
ENOV vs PODD Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, PODD has a market cap of 11.1B. Regarding current trading prices, ENOV is priced at $23.96, while PODD trades at $159.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas PODD's P/E ratio is 37.29. In terms of profitability, ENOV's ROE is -0.60%, compared to PODD's ROE of +0.21%. Regarding short-term risk, ENOV is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check PODD's competition here
ENOV vs MASI Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ENOV is priced at $23.96, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas MASI's P/E ratio is 44.54. In terms of profitability, ENOV's ROE is -0.60%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ENOV is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check MASI's competition here
ENOV vs BRKR Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, BRKR has a market cap of 8.7B. Regarding current trading prices, ENOV is priced at $23.96, while BRKR trades at $57.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas BRKR's P/E ratio is -238.50. In terms of profitability, ENOV's ROE is -0.60%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, ENOV is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check BRKR's competition here
ENOV vs BIO-B Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, BIO-B has a market cap of 8.3B. Regarding current trading prices, ENOV is priced at $23.96, while BIO-B trades at $307.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas BIO-B's P/E ratio is 51.10. In terms of profitability, ENOV's ROE is -0.60%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, ENOV is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check BIO-B's competition here
ENOV vs BIO Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, BIO has a market cap of 8B. Regarding current trading prices, ENOV is priced at $23.96, while BIO trades at $297.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas BIO's P/E ratio is 49.57. In terms of profitability, ENOV's ROE is -0.60%, compared to BIO's ROE of +0.02%. Regarding short-term risk, ENOV is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check BIO's competition here
ENOV vs GKOS Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, GKOS has a market cap of 7.4B. Regarding current trading prices, ENOV is priced at $23.96, while GKOS trades at $126.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas GKOS's P/E ratio is -38.21. In terms of profitability, ENOV's ROE is -0.60%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, ENOV is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check GKOS's competition here
ENOV vs NARI Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ENOV is priced at $23.96, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas NARI's P/E ratio is -59.24. In terms of profitability, ENOV's ROE is -0.60%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ENOV is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check NARI's competition here
ENOV vs LIVN Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, ENOV is priced at $23.96, while LIVN trades at $77.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas LIVN's P/E ratio is 39.37. In terms of profitability, ENOV's ROE is -0.60%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, ENOV is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check LIVN's competition here
ENOV vs IRTC Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, ENOV is priced at $23.96, while IRTC trades at $113.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas IRTC's P/E ratio is -133.92. In terms of profitability, ENOV's ROE is -0.60%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, ENOV is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check IRTC's competition here
ENOV vs AXNX Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ENOV is priced at $23.96, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ENOV's ROE is -0.60%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ENOV is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check AXNX's competition here
ENOV vs ITGR Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ITGR has a market cap of 3.2B. Regarding current trading prices, ENOV is priced at $23.96, while ITGR trades at $94.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ITGR's P/E ratio is 23.36. In terms of profitability, ENOV's ROE is -0.60%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, ENOV is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ITGR's competition here
ENOV vs TMDX Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, TMDX has a market cap of 2.6B. Regarding current trading prices, ENOV is priced at $23.96, while TMDX trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas TMDX's P/E ratio is 17.00. In terms of profitability, ENOV's ROE is -0.60%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, ENOV is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check TMDX's competition here
ENOV vs ESTA Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, ENOV is priced at $23.96, while ESTA trades at $79.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ESTA's P/E ratio is -54.30. In terms of profitability, ENOV's ROE is -0.60%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, ENOV is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check ESTA's competition here
ENOV vs AXGN Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, ENOV is priced at $23.96, while AXGN trades at $42.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas AXGN's P/E ratio is -66.98. In terms of profitability, ENOV's ROE is -0.60%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, ENOV is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check AXGN's competition here
ENOV vs NUVA Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ENOV is priced at $23.96, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ENOV's ROE is -0.60%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ENOV is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check NUVA's competition here
ENOV vs UFPT Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, ENOV is priced at $23.96, while UFPT trades at $231.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas UFPT's P/E ratio is 26.32. In terms of profitability, ENOV's ROE is -0.60%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ENOV is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check UFPT's competition here
ENOV vs PRCT Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, PRCT has a market cap of 1.6B. Regarding current trading prices, ENOV is priced at $23.96, while PRCT trades at $28.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas PRCT's P/E ratio is -15.73. In terms of profitability, ENOV's ROE is -0.60%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, ENOV is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check PRCT's competition here
ENOV vs IART Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, ENOV is priced at $23.96, while IART trades at $17.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas IART's P/E ratio is -2.77. In terms of profitability, ENOV's ROE is -0.60%, compared to IART's ROE of -0.48%. Regarding short-term risk, ENOV is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check IART's competition here
ENOV vs BFLY Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, BFLY has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $23.96, while BFLY trades at $5.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas BFLY's P/E ratio is -17.07. In terms of profitability, ENOV's ROE is -0.60%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, ENOV is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check BFLY's competition here
ENOV vs AHCO Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $23.96, while AHCO trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas AHCO's P/E ratio is -16.63. In terms of profitability, ENOV's ROE is -0.60%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, ENOV is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check AHCO's competition here
ENOV vs HSKA Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $23.96, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ENOV's ROE is -0.60%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ENOV is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check HSKA's competition here
ENOV vs ATEC Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $23.96, while ATEC trades at $8.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ATEC's P/E ratio is -9.95. In terms of profitability, ENOV's ROE is -0.60%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, ENOV is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check ATEC's competition here
ENOV vs IRMD Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $23.96, while IRMD trades at $96.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas IRMD's P/E ratio is 52.69. In terms of profitability, ENOV's ROE is -0.60%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, ENOV is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check IRMD's competition here
ENOV vs INSP Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $23.96, while INSP trades at $42.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas INSP's P/E ratio is 9.59. In terms of profitability, ENOV's ROE is -0.60%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ENOV is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check INSP's competition here
ENOV vs TNDM Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $23.96, while TNDM trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas TNDM's P/E ratio is -12.85. In terms of profitability, ENOV's ROE is -0.60%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, ENOV is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check TNDM's competition here
ENOV vs AVNS Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $23.96, while AVNS trades at $25.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas AVNS's P/E ratio is -15.64. In terms of profitability, ENOV's ROE is -0.60%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ENOV is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check AVNS's competition here
ENOV vs SILK Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $23.96, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas SILK's P/E ratio is -18.96. In terms of profitability, ENOV's ROE is -0.60%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ENOV is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SILK's competition here
ENOV vs CNMD Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $23.96, while CNMD trades at $36.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas CNMD's P/E ratio is 20.85. In terms of profitability, ENOV's ROE is -0.60%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, ENOV is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CNMD's competition here
ENOV vs FNA Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $23.96, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas FNA's P/E ratio is -19.83. In terms of profitability, ENOV's ROE is -0.60%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ENOV is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check FNA's competition here
ENOV vs AORT Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, AORT has a market cap of 1B. Regarding current trading prices, ENOV is priced at $23.96, while AORT trades at $20.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas AORT's P/E ratio is 83.48. In terms of profitability, ENOV's ROE is -0.60%, compared to AORT's ROE of +0.03%. Regarding short-term risk, ENOV is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check AORT's competition here
ENOV vs CSII Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ENOV is priced at $23.96, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas CSII's P/E ratio is -20.83. In terms of profitability, ENOV's ROE is -0.60%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ENOV is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check CSII's competition here
ENOV vs LMRI Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, LMRI has a market cap of 831.1M. Regarding current trading prices, ENOV is priced at $23.96, while LMRI trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas LMRI's P/E ratio is -22.18. In terms of profitability, ENOV's ROE is -0.60%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, ENOV is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check LMRI's competition here
ENOV vs INMD Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, INMD has a market cap of 824.6M. Regarding current trading prices, ENOV is priced at $23.96, while INMD trades at $13.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas INMD's P/E ratio is 10.04. In terms of profitability, ENOV's ROE is -0.60%, compared to INMD's ROE of +0.13%. Regarding short-term risk, ENOV is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check INMD's competition here
ENOV vs SSII Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, SSII has a market cap of 726.5M. Regarding current trading prices, ENOV is priced at $23.96, while SSII trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas SSII's P/E ratio is -72.60. In terms of profitability, ENOV's ROE is -0.60%, compared to SSII's ROE of -0.23%. Regarding short-term risk, ENOV is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check SSII's competition here
ENOV vs CRY Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, ENOV is priced at $23.96, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas CRY's P/E ratio is 425.71. In terms of profitability, ENOV's ROE is -0.60%, compared to CRY's ROE of +0.03%. Regarding short-term risk, ENOV is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check CRY's competition here
ENOV vs CBLL Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, CBLL has a market cap of 701.9M. Regarding current trading prices, ENOV is priced at $23.96, while CBLL trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas CBLL's P/E ratio is -11.42. In terms of profitability, ENOV's ROE is -0.60%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, ENOV is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check CBLL's competition here
ENOV vs SIBN Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, SIBN has a market cap of 688.7M. Regarding current trading prices, ENOV is priced at $23.96, while SIBN trades at $15.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas SIBN's P/E ratio is -39.82. In terms of profitability, ENOV's ROE is -0.60%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, ENOV is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SIBN's competition here
ENOV vs BVS Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, BVS has a market cap of 623.3M. Regarding current trading prices, ENOV is priced at $23.96, while BVS trades at $9.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas BVS's P/E ratio is 22.44. In terms of profitability, ENOV's ROE is -0.60%, compared to BVS's ROE of +0.16%. Regarding short-term risk, ENOV is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check BVS's competition here
ENOV vs SRDX Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ENOV is priced at $23.96, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ENOV's ROE is -0.60%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, ENOV is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SRDX's competition here
ENOV vs TCMD Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, TCMD has a market cap of 594.1M. Regarding current trading prices, ENOV is priced at $23.96, while TCMD trades at $26.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas TCMD's P/E ratio is 30.28. In terms of profitability, ENOV's ROE is -0.60%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check TCMD's competition here
ENOV vs APEN Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ENOV is priced at $23.96, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas APEN's P/E ratio is -9.43. In terms of profitability, ENOV's ROE is -0.60%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ENOV is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check APEN's competition here
ENOV vs BWAY Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, BWAY has a market cap of 566M. Regarding current trading prices, ENOV is priced at $23.96, while BWAY trades at $14.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas BWAY's P/E ratio is 65.59. In terms of profitability, ENOV's ROE is -0.60%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, ENOV is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check BWAY's competition here
ENOV vs NPCE Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, NPCE has a market cap of 544.1M. Regarding current trading prices, ENOV is priced at $23.96, while NPCE trades at $15.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas NPCE's P/E ratio is -24.55. In terms of profitability, ENOV's ROE is -0.60%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, ENOV is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check NPCE's competition here
ENOV vs ZIMV Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ENOV is priced at $23.96, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ENOV's ROE is -0.60%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, ENOV is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ZIMV's competition here
ENOV vs CTKB Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, CTKB has a market cap of 533.4M. Regarding current trading prices, ENOV is priced at $23.96, while CTKB trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas CTKB's P/E ratio is -7.12. In terms of profitability, ENOV's ROE is -0.60%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, ENOV is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check CTKB's competition here
ENOV vs CERS Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, CERS has a market cap of 517M. Regarding current trading prices, ENOV is priced at $23.96, while CERS trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas CERS's P/E ratio is -51.60. In terms of profitability, ENOV's ROE is -0.60%, compared to CERS's ROE of -0.15%. Regarding short-term risk, ENOV is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CERS's competition here
ENOV vs PMI Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, PMI has a market cap of 492.5M. Regarding current trading prices, ENOV is priced at $23.96, while PMI trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas PMI's P/E ratio is -0.42. In terms of profitability, ENOV's ROE is -0.60%, compared to PMI's ROE of +4.99%. Regarding short-term risk, ENOV is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check PMI's competition here
ENOV vs KIDS Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, KIDS has a market cap of 474.9M. Regarding current trading prices, ENOV is priced at $23.96, while KIDS trades at $18.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas KIDS's P/E ratio is -11.01. In terms of profitability, ENOV's ROE is -0.60%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ENOV is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check KIDS's competition here
ENOV vs VREX Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, VREX has a market cap of 447.1M. Regarding current trading prices, ENOV is priced at $23.96, while VREX trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas VREX's P/E ratio is -5.31. In terms of profitability, ENOV's ROE is -0.60%, compared to VREX's ROE of -0.18%. Regarding short-term risk, ENOV is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check VREX's competition here
ENOV vs PACB Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, PACB has a market cap of 425.5M. Regarding current trading prices, ENOV is priced at $23.96, while PACB trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas PACB's P/E ratio is -3.34. In terms of profitability, ENOV's ROE is -0.60%, compared to PACB's ROE of -4.88%. Regarding short-term risk, ENOV is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check PACB's competition here
ENOV vs CLPT Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, CLPT has a market cap of 407.6M. Regarding current trading prices, ENOV is priced at $23.96, while CLPT trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas CLPT's P/E ratio is -13.59. In terms of profitability, ENOV's ROE is -0.60%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, ENOV is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CLPT's competition here
ENOV vs DCTH Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, DCTH has a market cap of 403.6M. Regarding current trading prices, ENOV is priced at $23.96, while DCTH trades at $11.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas DCTH's P/E ratio is 1169.00. In terms of profitability, ENOV's ROE is -0.60%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, ENOV is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check DCTH's competition here
ENOV vs OFIX Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, OFIX has a market cap of 399M. Regarding current trading prices, ENOV is priced at $23.96, while OFIX trades at $9.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas OFIX's P/E ratio is -6.58. In terms of profitability, ENOV's ROE is -0.60%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, ENOV is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check OFIX's competition here
ENOV vs VMD Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, VMD has a market cap of 380.3M. Regarding current trading prices, ENOV is priced at $23.96, while VMD trades at $9.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas VMD's P/E ratio is 26.81. In terms of profitability, ENOV's ROE is -0.60%, compared to VMD's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check VMD's competition here
ENOV vs AVR Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, AVR has a market cap of 348.4M. Regarding current trading prices, ENOV is priced at $23.96, while AVR trades at $9.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas AVR's P/E ratio is -4.27. In terms of profitability, ENOV's ROE is -0.60%, compared to AVR's ROE of -1.24%. Regarding short-term risk, ENOV is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check AVR's competition here
ENOV vs LAB Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, LAB has a market cap of 345.9M. Regarding current trading prices, ENOV is priced at $23.96, while LAB trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas LAB's P/E ratio is -6.82. In terms of profitability, ENOV's ROE is -0.60%, compared to LAB's ROE of -0.21%. Regarding short-term risk, ENOV is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check LAB's competition here
ENOV vs SMLR Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ENOV is priced at $23.96, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ENOV's ROE is -0.60%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, ENOV is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SMLR's competition here
ENOV vs SENS Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, SENS has a market cap of 310.4M. Regarding current trading prices, ENOV is priced at $23.96, while SENS trades at $7.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas SENS's P/E ratio is -3.77. In terms of profitability, ENOV's ROE is -0.60%, compared to SENS's ROE of -1.30%. Regarding short-term risk, ENOV is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check SENS's competition here
ENOV vs MASS Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, MASS has a market cap of 302.1M. Regarding current trading prices, ENOV is priced at $23.96, while MASS trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas MASS's P/E ratio is -8.24. In terms of profitability, ENOV's ROE is -0.60%, compared to MASS's ROE of -0.26%. Regarding short-term risk, ENOV is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check MASS's competition here
ENOV vs ELMD Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ELMD has a market cap of 301.8M. Regarding current trading prices, ENOV is priced at $23.96, while ELMD trades at $36.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ELMD's P/E ratio is 31.15. In terms of profitability, ENOV's ROE is -0.60%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, ENOV is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ELMD's competition here
ENOV vs SGHT Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, SGHT has a market cap of 263.9M. Regarding current trading prices, ENOV is priced at $23.96, while SGHT trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas SGHT's P/E ratio is -6.93. In terms of profitability, ENOV's ROE is -0.60%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, ENOV is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check SGHT's competition here
ENOV vs MGRM Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ENOV is priced at $23.96, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas MGRM's P/E ratio is -11.11. In terms of profitability, ENOV's ROE is -0.60%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, ENOV is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check MGRM's competition here
ENOV vs TMCI Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, TMCI has a market cap of 242M. Regarding current trading prices, ENOV is priced at $23.96, while TMCI trades at $3.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas TMCI's P/E ratio is -3.89. In terms of profitability, ENOV's ROE is -0.60%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, ENOV is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check TMCI's competition here
ENOV vs CATX Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, CATX has a market cap of 231.4M. Regarding current trading prices, ENOV is priced at $23.96, while CATX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas CATX's P/E ratio is -2.12. In terms of profitability, ENOV's ROE is -0.60%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ENOV is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CATX's competition here
ENOV vs NVRO Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ENOV is priced at $23.96, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ENOV's ROE is -0.60%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ENOV is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check NVRO's competition here
ENOV vs EYES Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, ENOV is priced at $23.96, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas EYES's P/E ratio is N/A. In terms of profitability, ENOV's ROE is -0.60%, compared to EYES's ROE of -2.64%. Regarding short-term risk, ENOV is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check EYES's competition here
ENOV vs PROF Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, PROF has a market cap of 206.4M. Regarding current trading prices, ENOV is priced at $23.96, while PROF trades at $6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas PROF's P/E ratio is -5.50. In terms of profitability, ENOV's ROE is -0.60%, compared to PROF's ROE of -0.71%. Regarding short-term risk, ENOV is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check PROF's competition here
ENOV vs APYX Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, APYX has a market cap of 203.5M. Regarding current trading prices, ENOV is priced at $23.96, while APYX trades at $4.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas APYX's P/E ratio is -22.09. In terms of profitability, ENOV's ROE is -0.60%, compared to APYX's ROE of -0.91%. Regarding short-term risk, ENOV is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check APYX's competition here
ENOV vs RXST Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, RXST has a market cap of 203.3M. Regarding current trading prices, ENOV is priced at $23.96, while RXST trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas RXST's P/E ratio is -4.35. In terms of profitability, ENOV's ROE is -0.60%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ENOV is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check RXST's competition here
ENOV vs ANIK Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, ANIK has a market cap of 193.9M. Regarding current trading prices, ENOV is priced at $23.96, while ANIK trades at $14.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas ANIK's P/E ratio is -18.21. In terms of profitability, ENOV's ROE is -0.60%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, ENOV is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ANIK's competition here
ENOV vs BSGM Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ENOV is priced at $23.96, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ENOV's ROE is -0.60%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, ENOV is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check BSGM's competition here
ENOV vs MDGS Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ENOV is priced at $23.96, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ENOV's ROE is -0.60%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ENOV is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check MDGS's competition here
ENOV vs EDAP Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, ENOV is priced at $23.96, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas EDAP's P/E ratio is -5.80. In terms of profitability, ENOV's ROE is -0.60%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, ENOV is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check EDAP's competition here
ENOV vs INGN Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, INGN has a market cap of 171.9M. Regarding current trading prices, ENOV is priced at $23.96, while INGN trades at $6.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas INGN's P/E ratio is -6.98. In terms of profitability, ENOV's ROE is -0.60%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ENOV is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check INGN's competition here
ENOV vs FOCL Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, FOCL has a market cap of 171.7M. Regarding current trading prices, ENOV is priced at $23.96, while FOCL trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas FOCL's P/E ratio is -5.59. In terms of profitability, ENOV's ROE is -0.60%, compared to FOCL's ROE of -1.37%. Regarding short-term risk, ENOV is less volatile compared to FOCL. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check FOCL's competition here
ENOV vs QIPT Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ENOV is priced at $23.96, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ENOV's ROE is -0.60%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ENOV is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check QIPT's competition here
ENOV vs QTRX Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, QTRX has a market cap of 145.6M. Regarding current trading prices, ENOV is priced at $23.96, while QTRX trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas QTRX's P/E ratio is -1.31. In terms of profitability, ENOV's ROE is -0.60%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, ENOV is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check QTRX's competition here
ENOV vs CVRX Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, CVRX has a market cap of 138M. Regarding current trading prices, ENOV is priced at $23.96, while CVRX trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas CVRX's P/E ratio is -2.59. In terms of profitability, ENOV's ROE is -0.60%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, ENOV is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CVRX's competition here
ENOV vs MXCT Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, MXCT has a market cap of 127.5M. Regarding current trading prices, ENOV is priced at $23.96, while MXCT trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas MXCT's P/E ratio is -3.31. In terms of profitability, ENOV's ROE is -0.60%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, ENOV is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check MXCT's competition here
ENOV vs TLSI Comparison June 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.4B. In comparison, TLSI has a market cap of 126.6M. Regarding current trading prices, ENOV is priced at $23.96, while TLSI trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of -1.20, whereas TLSI's P/E ratio is -2.35. In terms of profitability, ENOV's ROE is -0.60%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, ENOV is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check TLSI's competition here